跳至主要内容
临床试验/NCT04031664
NCT04031664Unknown4 期

A Clinical Study on Qianjin Capsule of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Damp-heat Stasis and Qi Deficiency Syndrome):a Randomized, Double Blind, Parallel Control of Positive Drugs, Multi-center Clinical Study

China Academy of Chinese Medical Sciences0 个研究点目标入组 184 人开始时间: 2019年8月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
184
主要终点
The MCCormack scale scores of 184 subjects will be assessed

研究概览

简要总结

The purpose of this study is to evaluate the efficacy, safety of Qianjin Capsule of Gynaecology combined with antibiotics for pelvic inflammatory diseases (Damp-heat Stasis and Qi Deficiency Syndrome) for the short-term and long-term efficacy of traditional Chinese medicine in reducing the use of antibiotics, reducing the risk of clinical use of drugs.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

盲法说明

Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • (1) Women aged 20-50;
  • (2) Sexual History ;
  • (3) According to the diagnostic criteria of pelvic inflammatory diseases: according to the Diagnosis and Treatment Criteria of Pelvic Inflammatory Diseases (2014), the following specifications are as follows: A. uterine tenderness, or adnexal tenderness, or cervical lifting pain; B. axillary body temperature < 38 C. blood routine white blood cell count < 1.1 times the upper limit of normal value; D. blood routine neutrophil percentage < 90%; All of the above four items are available.

排除标准

  • (4)4<McCormack<12;
  • (5)TCM syndrome differentiation for damp-heat stagnation and Qi deficiency syndrome, A. lower abdominal pain; B. excessive amount of belt, yellow color, or odor; C. fatigue; D. tongue red, greasy fur, or with teeth marks, or blood stasis spots; the above four items are all available;
  • (6)Those who agree to participate in this clinical trial and sign the informed consent form.
  • Exclusion Criteria:
  • (1) Pregnant or recent (within 6 months) pregnant women, lactating women ;
  • (2) To identify the pathogen as Neisseria gonorrhoeae;
  • (3) Symptoms related to appendicitis, ectopic pregnancy, torsion or rupture of ovarian cyst pedicle, gastroenteritis, endometriosis, adenomyosis, trichomonal vaginitis, vulvovaginal candidiasis, bacterial vaginosis, etc.;
  • (4)Those with critical condition or surgical indications, such as fallopian tube and ovary abscess, pelvic abscess, diffuse peritonitis, septicemia;
  • (5)In patients with severe primary diseases such as heart, brain and hematopoietic system, ALT of liver function is higher than the upper limit of normal value, and Cr of renal function is higher than the upper limit of normal value;
  • (6)One month before admission, Chinese and Western medicines were used to treat the disease, which made it difficult to judge the efficacy of drugs;
  • (7)Anaphylactic constitution or persons known to be allergic to the medicines and their components used in this test ;
  • (8)Researchers do not consider it appropriate to participate in this clinical trial;
  • (9)Suspected or true history of alcohol and drug abuse, or other pathological changes or conditions that reduce the likelihood of enrollment or complicate enrollment, such as frequent changes in the working environment, unstable living environment, etc., are liable to lead to lost interviews, according to the judgement of researchers;
  • (10)Participation in other clinical researchers within 3 months before admission;
  • (11)Patients with suspected or confirmed quinolone contraindications, central or peripheral neuropathy, epilepsy, and depression

研究组 & 干预措施

Qianjin Capsule of Gynaecology

Experimental

On the basis of the antibiotic levofloxacin + metronidazole for 14 days, Gynecological Qianjin Capsule for 28 days.

One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc.

干预措施: Qianjin Capsule of Gynaecology (Drug)

Antibiotics alone group

Placebo Comparator

Levofloxacin + metronidazole for 14 days, and gynecological Qianjin capsule simulator for 28 days.

One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gramnegative bacteria. Bacterial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc.

干预措施: Qianjin Capsule of Gynaecology (Drug)

结局指标

主要结局

The MCCormack scale scores of 184 subjects will be assessed

时间窗: Change from base line on the 56 days after discontinuation

assessment of the 70% reduction rate after treatment

次要结局

  • The fibrinogen determination from hemorheological tests of 184 participants will be assessed(Change from base line on the 28 day of medication.)
  • The white blood cells of 184 participants will be assessed(Change from base line on the 28 days of medication and 56 days after discontinuation)
  • The TCM syndrome scores of 184 subjects will be assessed(Change from base line on the 56 days after discontinuation)
  • The VAS score of 184 subjects will be assessed(Change from base line on the 56 days after discontinuation)
  • The volume of liquid on B-mode of 184 subjects will be assessed(After 28 days of medication)
  • The neutrophils of 184 participants will be assessed(Change from base line on the 28 days of medication and 56 days after discontinuation)
  • The plasma viscosity from hemorheological tests of 184 participants will be assessed(Change from base line on the 28 day of medication.)
  • The CRP of 184 participants will be assessed(Change from base line on the 28 day of medication.)
  • The whole blood reduced viscosity from hemorheological tests of 184 participants will be assessed(Change from base line on the 28 day of medication.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Yanming Xie

Deputy director

China Academy of Chinese Medical Sciences

相似试验